| http://dbpedia.org/ontology/abstract
|
Zaurategrast (CDP323) ist ein experimentel … Zaurategrast (CDP323) ist ein experimenteller Arzneistoff, der auf seine Eignung zur Behandlung der multiplen Sklerose (MS) untersucht wurde. Es handelt sich um einen α4-Integrin-Hemmer. Zaurategrast ist ein kleines chemisches Molekül, das als prodrug zum Einsatz kommt.olekül, das als prodrug zum Einsatz kommt.
, Zaurategrast (CDP323) is a small-molecule … Zaurategrast (CDP323) is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to α4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and was a putative new drug for oral treatment of multiple sclerosis. In October 2006, UCB and Biogen Idec announced a collaboration to jointly develop and commercialize zaurategrast for the treatment of multiple sclerosis and other potential indications. In June 2009, development of zaurategrast was discontinued due to discouraging results of a Phase II clinical trial.ging results of a Phase II clinical trial.
, CDP323 is een kleine molecule die onderzocht werd als therapie voor multiple sclerose. Het was in ontwikkeling door UCB en had de eerste orale M.S.-remmer kunnen worden.
|
| http://dbpedia.org/ontology/casNumber
|
455264-31-0
|
| http://dbpedia.org/ontology/fdaUniiCode
|
06A0IC74I3
|
| http://dbpedia.org/ontology/pubchem
|
10186367
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Zaurategrast.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://clinicaltrials.gov/search/intervention=CDP323 +
|
| http://dbpedia.org/ontology/wikiPageID
|
13219252
|
| http://dbpedia.org/ontology/wikiPageLength
|
6972
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1113810198
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/UCB_%28company%29 +
, http://dbpedia.org/resource/Blood_vessel +
, http://dbpedia.org/resource/Category:Organobromides +
, http://dbpedia.org/resource/Consecutive +
, http://dbpedia.org/resource/Inflammation +
, http://dbpedia.org/resource/VCAM-1 +
, http://dbpedia.org/resource/Mechanism_of_action +
, http://dbpedia.org/resource/United_States +
, http://dbpedia.org/resource/Receptor_antagonist +
, http://dbpedia.org/resource/Category:Spiro_compounds +
, http://dbpedia.org/resource/Natalizumab +
, http://dbpedia.org/resource/Experimental_autoimmune_encephalomyelitis +
, http://dbpedia.org/resource/Disease +
, http://dbpedia.org/resource/Interferon-beta +
, http://dbpedia.org/resource/Europe +
, http://dbpedia.org/resource/United_Kingdom +
, http://dbpedia.org/resource/Category:Immunosuppressants +
, http://dbpedia.org/resource/Prophylaxis +
, http://dbpedia.org/resource/Adverse_event +
, http://dbpedia.org/resource/Tolerability +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Biogen_Idec +
, http://dbpedia.org/resource/Category:Abandoned_drugs +
, http://dbpedia.org/resource/Therapy +
, http://dbpedia.org/resource/Celltech +
, http://dbpedia.org/resource/Immune_cell +
, http://dbpedia.org/resource/Brain +
, http://dbpedia.org/resource/Category:Naphthyridines +
, http://dbpedia.org/resource/Prodrug +
, http://dbpedia.org/resource/Category:Cyclobutenes +
, http://dbpedia.org/resource/Multiple_sclerosis +
, http://dbpedia.org/resource/Pharmacokinetics +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Mouse +
, http://dbpedia.org/resource/Mouth +
, http://dbpedia.org/resource/Tissue_%28biology%29 +
, http://dbpedia.org/resource/Indication_%28medicine%29 +
, http://dbpedia.org/resource/Reaction_inhibitor +
, http://dbpedia.org/resource/Integrin +
, http://dbpedia.org/resource/Category:Propionic_acids +
, http://dbpedia.org/resource/Investigational_New_Drug +
, http://dbpedia.org/resource/Placebo +
|
| http://dbpedia.org/property/br
|
1
|
| http://dbpedia.org/property/c
|
26
|
| http://dbpedia.org/property/casNumber
|
455264
|
| http://dbpedia.org/property/chemspiderid
|
8361869
|
| http://dbpedia.org/property/h
|
25
|
| http://dbpedia.org/property/iupacName
|
-2
|
| http://dbpedia.org/property/legalStatus
|
Investigational
|
| http://dbpedia.org/property/n
|
4
|
| http://dbpedia.org/property/o
|
3
|
| http://dbpedia.org/property/pubchem
|
10186367
|
| http://dbpedia.org/property/smiles
|
C1CCC2CN[C@@H]CO
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
KYHVWHYLKOHLKA-FQEVSTJZSA-N
|
| http://dbpedia.org/property/synonyms
|
CDP323
|
| http://dbpedia.org/property/unii
|
6
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Infobox_drug +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Immunosuppressants +
, http://dbpedia.org/resource/Category:Abandoned_drugs +
, http://dbpedia.org/resource/Category:Propionic_acids +
, http://dbpedia.org/resource/Category:Cyclobutenes +
, http://dbpedia.org/resource/Category:Naphthyridines +
, http://dbpedia.org/resource/Category:Spiro_compounds +
, http://dbpedia.org/resource/Category:Organobromides +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Zaurategrast?oldid=1113810198&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Zaurategrast.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Zaurategrast +
|
| owl:sameAs |
http://dbpedia.org/resource/Zaurategrast +
, http://de.dbpedia.org/resource/Zaurategrast +
, http://nl.dbpedia.org/resource/CDP323 +
, http://yago-knowledge.org/resource/Zaurategrast +
, http://www.wikidata.org/entity/Q166806 +
, https://global.dbpedia.org/id/dva9 +
|
| rdf:type |
http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
|
| rdfs:comment |
Zaurategrast (CDP323) ist ein experimentel … Zaurategrast (CDP323) ist ein experimenteller Arzneistoff, der auf seine Eignung zur Behandlung der multiplen Sklerose (MS) untersucht wurde. Es handelt sich um einen α4-Integrin-Hemmer. Zaurategrast ist ein kleines chemisches Molekül, das als prodrug zum Einsatz kommt.olekül, das als prodrug zum Einsatz kommt.
, Zaurategrast (CDP323) is a small-molecule … Zaurategrast (CDP323) is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to α4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and was a putative new drug for oral treatment of multiple sclerosis. for oral treatment of multiple sclerosis.
, CDP323 is een kleine molecule die onderzocht werd als therapie voor multiple sclerose. Het was in ontwikkeling door UCB en had de eerste orale M.S.-remmer kunnen worden.
|
| rdfs:label |
Zaurategrast
, CDP323
|
